As of November 15, 2026, Sunshine Biopharma Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 5, 2026, naming 1 departure. The latest filing names Abderrazzak Merzouki, leaving (Form 8-K, February 5, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Sunshine Biopharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Sunshine Biopharma Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-05. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Sunshine Biopharma Inc. files it.
Also on the record for Sunshine Biopharma Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 9.99% of the class | 5%+ stakes | Source |
| October 14, 2026 | Stake report, Schedule 13G, by BJI Financial Group | 6% of the class | 5%+ stakes | Source |
| October 13, 2026 | Stake report, Schedule 13G, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| October 5, 2026 | Stake report, Schedule 13G/A, by Alta Partners LLC | 4.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by L1 Capital Global Opportunities Master Fund, Ltd. | 4.99% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 9.99% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G, by Alta Partners LLC | 8.6% of the class | 5%+ stakes | Source |
| May 22, 2026 | Stake report, Schedule 13G, by L1 Capital Global Opportunities Master Fund, Ltd. | 5.83% of the class | 5%+ stakes | Source |
| May 21, 2026 | Stake report, Schedule 13G, by Bigger Michael | 9.47% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Altium Capital Management LLC | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Sunshine Biopharma Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Sunshine Biopharma Inc. and the records around it.
Sunshine Biopharma Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Altium Capital Management LLC also filed stake reports on 5 other companies: Expion360 Inc. (Nov 2025), Femto Technologies Inc (Aug 2025), LogicMark, Inc. (Aug 2025)
- BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies: Neuraxis, INC (Nov 2026), ClearPoint Neuro, Inc. (Nov 2026), Dermata Therapeutics, Inc. (Nov 2026)
- Alta Partners LLC also filed stake reports on 26 other companies: Robin Energy Ltd. (Oct 2026), Huachen AI Parking Management Technology Holding Co., Ltd (Oct 2026), C3is Inc. (Oct 2026)
Watch Sunshine Biopharma Inc.
Get an email when Sunshine Biopharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sunshine Biopharma Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sunshine Biopharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sunshine Biopharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-05 | Out | 8-K, 2026-02-05 |
Why did they leave? What the filings say
Sunshine Biopharma Inc.'s filings state no reason for the departures below. Where a filing gives none, it says so here; nothing is inferred.
- Abderrazzak Merzouki (filed 2026-02-05): the filing states no reason.
New leaders reset buying decisions — get the Full Report on Sunshine Biopharma Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Sunshine Biopharma Inc., with the record behind each one.
Find candidates like senior executive at Sunshine Biopharma Inc.Every change, in the filing's words
Departing: Abderrazzak Merzouki
On February 5, 2026, Dr. Abderrazzak Merzouki resigned as chief operating officer of Sunshine Biopharma Inc., effective immediately. 2
Tools for this story
Each opens in a new tab, filled in for Sunshine Biopharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
